Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 1400 of 3499 entries
View as:

Integrating Use of Self-Affirmation Content Into a Mobile App to Promote Quit Attempts With Text-Based Smoking Cessation Intervention Messaging

Phase: N/A Priority: Normal
NCT ID: NCT03027466 Org: User:
Start: 03/06/18 End: 09/01/19 Due: 09/01/20

Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)

Phase: N/A Priority: Normal
NCT ID: NCT00340548 Org: User:
Start: 04/09/02 End: 01/09/20 Due: 01/09/21

ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00006106 Org: User:
Start: 07/31/99 End: - Due: -

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

Phase: N/A Priority: Normal
NCT ID: NCT07012031 Org: User:
Start: 09/30/25 End: 06/14/27 Due: 06/14/28

A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00108732 Org: User:
Start: 02/28/06 End: 10/31/10 Due: 10/31/11

Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00058279 Org: User:
Start: 02/28/03 End: 08/31/06 Due: 08/31/07

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

Phase: N/A Priority: Normal
NCT ID: NCT00001564 Org: User:
Start: 12/23/96 End: 10/25/07 Due: 10/25/08

EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01251926 Org: User:
Start: 11/15/10 End: 04/23/14 Due: 04/23/15

A Study Comparing the Combination of Dasatinib or Imatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Phase: N/A Priority: Normal
NCT ID: NCT06124157 Org: User:
Start: 05/30/25 End: 12/01/30 Due: 12/01/31

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Phase: N/A Priority: Normal
NCT ID: NCT06126276 Org: User:
Start: 05/07/24 End: 02/20/27 Due: 02/20/28

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Phase: N/A Priority: Normal
NCT ID: NCT04548752 Org: User:
Start: 02/22/21 End: 10/01/26 Due: 10/01/27

AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00303862 Org: User:
Start: 03/31/06 End: 03/31/11 Due: 03/31/12

Diindolylmethane in Preventing Cancer in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00784394 Org: User:
Start: 04/30/04 End: 10/31/09 Due: 10/31/10

Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00033358 Org: User:
Start: 02/28/02 End: - Due: -

Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06161545 Org: User:
Start: 07/02/25 End: 12/01/27 Due: 12/01/28

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Phase: N/A Priority: Normal
NCT ID: NCT06172296 Org: User:
Start: 04/19/24 End: 12/31/29 Due: 12/31/30

A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...

Phase: N/A Priority: Normal
NCT ID: NCT05621291 Org: User:
Start: 07/02/25 End: 12/31/27 Due: 12/31/28

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

Phase: N/A Priority: Normal
NCT ID: NCT04929041 Org: User:
Start: 10/07/22 End: 12/31/27 Due: 12/31/28

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01352962 Org: User:
Start: 09/26/11 End: 07/06/18 Due: 07/06/19

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01434316 Org: User:
Start: 11/11/11 End: 08/02/25 Due: 08/02/26

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01811212 Org: User:
Start: 05/08/13 End: 10/09/17 Due: 10/09/18

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05642195 Org: User:
Start: 07/02/25 End: 12/30/35 Due: 12/30/36

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06311227 Org: User:
Start: 08/13/25 End: 05/20/27 Due: 05/20/28

Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00459342 Org: User:
Start: 03/31/07 End: 04/30/12 Due: 04/30/13

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04284787 Org: User:
Start: 02/16/21 End: 01/30/26 Due: 01/30/27